Equities

Epigenomics AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Epigenomics AG

Actions
  • Price (EUR)0.87
  • Today's Change-0.01 / -1.14%
  • Shares traded3.11k
  • 1 Year change+8.75%
  • Beta0.9299
Data delayed at least 15 minutes, as of Feb 10 2026 07:18 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.

  • Revenue in EUR (TTM)4.00k
  • Net income in EUR-2.76m
  • Incorporated2000
  • Employees3.00
  • Location
    Epigenomics AGZiegelhaeuser Landstrasse 3HEIDELBERG 69120GermanyDEU
  • Phone+49 62 216492487
  • Fax+49 62 216492472
  • Websitehttps://www.epigenomics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
bioXXmed AG3.49k-996.91k365.45k1.00--1.11--104.71-5.23-5.230.01761.170.006--0.05723,490.00-170.22-39.81-206.00-40.13-----28,564.76-25,207.92---6.950.00---79.94-37.3695.24------
Oxurion NV2.00k1.96m490.69k11.000.0114--0.2421245.340.61370.61370.0006-3.760.0004--0.0015181.8241.10-101.52---249.96-650.0053.8597,950.00-2,672.68---------98.86-76.22100.63------
MediGene AG-100.00bn-100.00bn595.50k87.00--0.03----------1.33-----------22.31---25.28--90.15---123.17----0.1146---80.69-4.89-94.20---8.12--
Lidds AB0.00-524.65k641.88k1.00--4.57-----0.0409-0.04090.000.01090.00----0.00-99.68-64.76-119.64-76.72---1,554.86---2,637.08----0.00------85.23---65.39--
Epigenomics AG4.00k-2.76m765.43k3.00------191.36-3.14-3.140.00460.000.0003----2,000.00-23.10-55.09-23.17-61.61-2,300.00-0.2095-69,025.00-473.65----1.00---100.00--24.90------
PCI Biotech Holding ASA410.83k-1.80m781.79k7.00--0.7128--1.90-0.5502-0.55020.12560.33530.1676--0.896669,714.30-73.44-41.44-92.22-46.61-----438.10-897.91----0.022--125.25-6.4319.19------
GeNeuro SA0.00-14.76m916.64k19.00---------0.594-0.5940.00-0.55480.00----0.00-165.51-96.43-356.72-185.61---------------------20.96---20.13--
Shortwave Life Sciences PLC52.52k-295.35k997.76k2.00--0.2391--19.00-0.007-0.0070.00120.06690.0155--2.2622,850.00-8.73---9.00--99.34---562.34------0.00---19.39--76.00------
Data as of Feb 10 2026. Currency figures normalised to Epigenomics AG's reporting currency: Euro EUR

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Axxion SA (Luxembourg)as of 30 Jun 202520.000.00%
Data from 30 Jan 2026 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.